BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8774651)

  • 1. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
    Geisler JP; Wiemann MC; Miller GA; Geisler HE
    Gynecol Oncol; 1996 Mar; 60(3):424-7. PubMed ID: 8774651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
    Liu JF; Hirsch MS; Lee H; Matulonis UA
    Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
    Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
    Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor.
    Kieback DG; McCamant SK; Press MF; Atkinson EN; Gallager HS; Edwards CL; Hajek RA; Jones LA
    Cancer Res; 1993 Nov; 53(21):5188-92. PubMed ID: 8221656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
    De Sousa Damião R; Fujiyama Oshima CT; Stávale JN; Gonçalves WJ
    Oncol Rep; 2007 Jul; 18(1):25-32. PubMed ID: 17549341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY; Xi MR; Yang KX; Yu H
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
    Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H
    J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
    Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
    J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].
    Kieback DG; Press MF; McCamant SK; Atkinson EN; Möbus VJ; Runnebaum IB; Kreienberg R; Jones LA
    Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):189-94. PubMed ID: 7789706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
    Bristow RE; Duska LR; Montz FJ
    Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of p53 in epithelial ovarian cancer.
    Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
    Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
    Kommoss S; Rochon J; Harter P; Heitz F; Grabowski JP; Ewald-Riegler N; Haberstroh M; Neunhoeffer T; Barinoff J; Gomez R; Traut A; du Bois A
    Ann Surg Oncol; 2010 Jan; 17(1):279-86. PubMed ID: 19898901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ovarian cancer prognosis and expression of receptors to sex hormones and proliferative activity of tumor cells].
    Novichkov EV; Votintsev AA
    Arkh Patol; 2006; 68(2):10-3. PubMed ID: 16752501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer.
    McCann CK; Growdon WB; Munro EG; Del Carmen MG; Boruta DM; Schorge JO; Goodman A
    Ann Surg Oncol; 2011 Oct; 18(10):2912-8. PubMed ID: 21424880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.